Physician profile
Remi Trien
NPI 1639465057
$2,029.35
in general payments reported to CMS, 2019-2025
12 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.26 · 2020: $44.95 · 2021: $722 · 2022: $483 · 2023: $296 · 2024: $292 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $725.98 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $362.89 | 2019-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $252.13 | 2021-2022 | |
| Pfizer INC. | $187.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.59 | 2021-2025 | Lokelma, Tagrisso |
| Inspire Medical Systems, INC. | $96.64 | 2024 | Inspire |
| Astellas Pharma US INC | $75.30 | 2023-2024 | Cresemba |
| Abbvie INC. | $48.04 | 2023-2025 | Dalvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.11 | 2021-2022 | |
| Melinta Therapeutics, LLC | $23.04 | 2025 | Kimyrsa, Rezzayo |
| Alexion Pharmaceuticals, INC. | $19.55 | 2021 | |
| Chiesi USA, INC. | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remi Trien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.